
Accepted Manuscript

Title: Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression

Author: Noah Isakov



PII:	S1044-579X(17)30108-6
DOI:	http://dx.doi.org/doi:10.1016/j.semcancer.2017.04.012
Reference:	YSCBI 1324
To appear in:	Seminars in Cancer Biology
Received date:	26-1-2017
Revised date:	22-3-2017
Accepted date:	25-4-2017

Please cite this article as: Isakov Noah.Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression.*Seminars in Cancer Biology* http://dx.doi.org/10.1016/j.semcancer.2017.04.012

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression

Noah Isakov^{*,‡}

^{*}The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences and the Cancer Research Center, Ben Gurion University of the Negev, P.O.B. 653, Beer Sheva 84105, Israel

[‡]Corresponding author: The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel. Tel. 972-8-6477267; FAX 972-8-6477626. E-mail address: noah@bgu.ac.il

Abstract

- 1. Introduction
- 2. PKC is the cellular receptor for tumor-promoting phorbol esters
- 3. PKC structure and function
- 4. Regulation of PKC activity
- 5. PKC in cancer diseases
 - 5a. Involvement of PKCɛ in cancer diseases
 - 5b. The role of PKC_ɛ in chemical carcinogenesis
 - 5c. PKCε as a regulator of apoptosis
 - 5d. Regulation of tumor cell growth and motility by PKCE
 - 5e. Involvement of PKCα and PKCβ isoforms in cancer diseases
 - 5f. Involvement of atypical PKC isoforms in cancer diseases
- 6. Drug targeting and modulation of PKC
 - 6a. Inhibition of upstream regulators of PKC
 - 6b. ATP-competitive small-molecule inhibitors
 - 6c. C1 domain-binding DAG mimetic compounds
 - 6d. C2 and PB1 domain-directed inhibitors
 - 6e. Additional inhibitors of PKC interaction with binding protein
 - 6f. Antisense oligonucleotide inhibitors

Download English Version:

https://daneshyari.com/en/article/8361785

Download Persian Version:

https://daneshyari.com/article/8361785

Daneshyari.com